Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Updated results of a first-in-human, Phase Ⅰa/Ⅰb study of QLS32015 (GPRC5D×CD3) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Gang An, Baijun Fang, Xiaobing Huang, Yan Xu, Fei Li, Zhen Cai, Xiaojing Yan, Xianqi Feng, Wuping Li, Xiangmin Tong, Zengjun Li, Yuzhang Liu, Feifei Che, Xin'ai Yang, Xianlin Duan, Peng Shao, Xiaoyan Kang, Lugui Qiu

Blood (2025) 146 (Supplement 1): 4049.

https://doi.org/10.1182/blood-2025-4049

Published: 2025

Journal Articles

QLS4131, a next-generation GPRC5D×BCMA×CD3 trispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM): Initial results of a first-in-human Phase Ⅰa study

Gang An, Yafei Wang, Hui Guo, Wanhong Zhao, Xiaobing Huang, Zhongjun Xia, Jian Chen, Xianlin Duan, Zeyu Yang, Xiaoyan Kang, Lugui Qiu

Blood (2025) 146 (Supplement 1): 5831.

https://doi.org/10.1182/blood-2025-5831

Published: 2025

Journal Articles

First-in-Human, Phase Ia , Dose Escalation, Monotherapy Study of QLS32015, a Novel GPRC5D×CD3 T-Cell Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Lu-Gui Qiu, Gang An, Baijun Fang, Xiaobing Huang, Yan Xu, Yuzhang Liu, Feifei Che, Xinai Yang, Xianlin Duan, Peng Shao, Xiaoyan Kang

Blood (2024) 144 (Supplement 1): 1990.

https://doi.org/10.1182/blood-2024-201960

Published: 2024